

Special Issue

The Vasoactive Intestinal Peptide Receptor Axis in Translational Medicine: Therapeutic Opportunities and Biomarker Potential

Message from the Guest Editors

Vasoactive intestinal peptide (VIP) is a pleiotropic peptide involved in neuroendocrine-immune communication, inflammation, immune tolerance, tissue homeostasis and repair. Through its receptors, mainly VPAC1 and VPAC2, VIP regulates key cellular and molecular pathways that have attracted growing interest for the development of novel therapeutic approaches.

This Special Issue aims to provide an updated and multidisciplinary view of the therapeutic potential of VIP, VIP analogues and VIP receptor-targeted strategies. Original research articles and reviews addressing disease mechanisms, receptor signaling, receptor-selective ligands, pharmacological optimization, innovative delivery systems, and preclinical or clinical applications are welcome. Contributions exploring VIP and its receptors as biomarkers, as well as their role in patient stratification and precision medicine, are also encouraged.

Guest Editors

Prof. Dr. Carmen Martínez

1. Musculoskeletal Pathology Group, San Carlos Health Research Institute (IdiSSC) (ROR 04d0ybj29), 28040 Madrid, Spain
2. Departmental Section of Cell Biology and Histology, Faculty of Medicine, Complutense University of Madrid (ROR 02p0gd045), Madrid, Spain

Dr. Yasmina Juarranz

1. Musculoskeletal Pathology Group, San Carlos Health Research Institute (IdiSSC) (ROR 04d0ybj29), 28040 Madrid, Spain
2. Department of Cell Biology and Histology, Faculty of Biological Science, Complutense University of Madrid (ROR 02p0gd045), Madrid, Spain

Deadline for manuscript submissions

15 January 2027



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/283844

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)